Semi-synthetic bile acid could be a promising therapeutic option for TH17-mediated intestinal diseases Post author:admin Post published:March 15, 2025 Post category:uncategorized A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation. You Might Also Like Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC September 8, 2025 Concerns grow over quality of care as investor groups buy not-for-profit nursing homes March 13, 2024 Breakthrough study defines ideal interval for immunotherapy and liver transplants March 6, 2025
Concerns grow over quality of care as investor groups buy not-for-profit nursing homes March 13, 2024